Navigation Links
Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
Date:9/14/2007

HAMBURG, Germany, Sept. 14 /PRNewswire/ -- Indivumed announces today that a service agreement with Roche Diagnostics GmbH was signed. Within this agreement Indivumed will apply its automated immunohistochemistry service platform for analyzing various biomarkers and drug targets in the area of oncology. Indivumed will provide for this project a selection of tumor tissue sections from its tumor biobank as well as specifically collected clinical samples. The analysis of specific biomarkers and drug targets should enable Roche to efficiently develop novel targeted therapies for cancer.

Indivumed is a privately held biotech company focused on the generation, characterization and analysis of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Kensington, Maryland, USA, Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of over 6500 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's internal cancer research in biomarkers and primary cell drug screening as well as for the use of pharmaceutical and biopharma partners through tumor biobank access and IHC services.


'/>"/>
SOURCE Indivumed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. CDW buyer supports Berbee growth plans
2. Tech center supports energy-saving device for heat-treating plants
3. Inacom Supports Blackhawk Technology Mentor Program
4. Computer Card Supports Solo Doctor
5. Federal Funding Supports Small Business Innovation
6. Advantages of Roche Applied Science amplification products
7. Roche Diagnostics Corporation
8. Roche Diagnostics Corporation
9. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
10. Prodesse enters patent agreement with Roche
11. A prognosis for GE and Abbott Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
Breaking Biology Technology:
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):